Active Pharmaceutical Ingredients (API) Market, By Product Type (Low Potent APIs, High Potent APIs), By Molecular Type (Small Molecules, Large Molecules), By Formulation (Oral, Topical, Injectables, Drops), By Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, Ophthalmic, Respiratory, Dermatology, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI738

Pages :310

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Active Pharmaceutical Ingredients Market : Key Developments

On August 29, 2023, EUROAPI, a leading small molecules API manufacturer, and the shareholders of BianoGMP, a contract development and manufacturing organization, with recognized expertise in oligonucleotides, signed a share purchase and transfer agreement under which EUROAPI will acquire 100% of Biano shares.

On August 2, 2023, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company, announced that it has closed the previously announced private placement with Rafael Holdings, Inc. for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants to purchase an additional 4,000,000 shares of common stock of Cyclo Therapeutics, for an aggregate purchase price of US$5,000,000.

In November 2022, EIB, the European Union’s (EU) long-term financing institution, and MedinCell, a pharmaceutical company, signed a new US$41 million loan agreement to support the development of innovative treatments. The new loan signed between the European Investment Bank (EIB), backed by the Investment Plan for Europe, and pharmaceutical company MedinCell is intended to support the development of the company’s portfolio of innovative. MedinCell’s portfolio is already composed of several long-active injectables products at preclinical and clinical stages.

In November 2022, GE Healthcare, the world’s leading supplier of contrast media, announced an US$80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway.